Merck & Co. faces multiple lawsuits

According to Consumer Drug Report, a drug information resource, pharmaceutical company Merck & Co. is currently facing multiple lawsuits. Two women claim to have suffered osteonecrosis of the jaw (ONJ), or “dead jaw”, after taking Fosamax® and have filed lawsuits against Merck. Opening statements were heard on March 1, 2012.

According to Merck, the two women suffered from medical conditions that cause jaw injuries prior to taking Fosamax and maintain that Fosamax did not cause their injuries.

In addition to the claims brought forth by women who have suffered osteonecrosis after taking Fosamax, women have made claims that Fosamax causes atypical femur fractures. According to their complaints, spontaneous femur fractures would occur during normal activities such as walking or jogging.

There are two separate multidistrict litigation trials for Fosamax lawsuits. All femur fracture lawsuits are currently consolidated in the U.S. District Court for the District of New Jersey and all osteonecrosis lawsuits are consolidated in the U.S. District Court for the Southern Court for the Southern District of New York.

Merck introduced Fosamax in October of 1995 for the treatment of osteoporosis, a chronic bone condition that causes bones to become weak and fragile. Fosamax is included in a class of drugs known as bisphosphonates, which are bone strengthening medications.

In addition to Fosamax, Merck also manufactures a drug known as Vytorin® which helps lower the amount of cholesterol and involves a combination of Zocor® and Zetia®. Vytorin is a competing drug to Zocor and is much more expensive.

A shareholder lawsuit was filed against Merck claiming that Merck jointly marketed Vytorin, with the help of Schering-Plough Corp., as being more effective than Zocor and concealed the results of a study that showed otherwise. The lawsuit was settled and Merck agreed to pay $5.1 million to cover plaintiff fees.

Fosamax® lawsuit attorneys actively pursue Fosamax injury claims

Fosamax lawsuit attorneys are actively pursuing claims against drug manufacturer Merck & Co. for reported adverse side effects associated with prescription drug Fosamax. Currently, the pharmaceutical giant faces a large number of lawsuits filed by individuals who claim to have suffered femur fracture injuries among other injuries.

In 1995, the Food and Drug Administration (FDA) approved Fosamax use to treat a chronic condition known as osteoporosis. The drug works by strengthening bones and preventing breakage. However, claims have been reported to the FDA stating that Fosamax and other bisphosphonate drugs cause atypical femur fractures.

A causal linkage between long term use (considered to be 12 months or more) and femur fractures were determined in recent studies conducted by researchers of bisphosphonates. It was shown that drugs like Fosamax tend to slow down the rate at which the body replaces old bone with new bone leading to possible fractures which may be serious and life threatening. Some patients claim that femur fractures would occur spontaneously, especially during running or jogging.

The FDA issued a warning to consumers and health professionals regarding the increased risk for suffering femur fractures in 2008. In 2010, the FDA mandated that all bisphosphonate manufacturers update their warning labels to include the increased risk for fracture with long term use.

Other injuries allegedly caused by Fosamax include osteonecrosis of the jaw (ONJ) or “dead jaw,” atrial fibrillation, and esophageal cancer. Currently all femur fracture lawsuits have been consolidated and centralized in the U.S. District Court for the District of New Jersey.

U.S. District Judge John Keenan ordered three Fosamax bellwether trials to occur this year, one in May, September, and November. Each Fosamax lawsuit against Merck alleges that the company failed to properly issue sufficient warnings regarding the risk for femur fracture injuries.

Femur Fracture lawsuits consolidated to one MDL

Femur fracture lawsuits filed by women who have taken Fosamax®, Boniva®, and Reclast®, which are included in a class of drugs known as bisphosphonates, will all be consolidated into a single multidistrict litigation, according to Consumer Drug Report, a medical drug information resource. Women who have taken these medications for the treatment of osteoporosis claim to have suffered femur fractures as a result of long term use.

Merck & Co., the manufacturer of Fosamax currently faces over a thousand lawsuits filed by women across the United States. Each lawsuit includes similar allegations that Merck failed to properly warn regarding the long term side effects of Fosamax. Three bellwether trials are scheduled this year and will help the courts predict future trends throughout litigation.

All Fosamax lawsuits are currently consolidated before Judge Garrett E. Brown for pretrial proceedings in the U.S. District Court for the District of New Jersey.

Several Boniva and Reclast femur fracture lawsuits have already been added to the Fosamax MDL. Theresa Thomas- Walsh claims that while taking Fosamax, Boniva, and Reclast, she suffered both right and left femur fractures. Her case was also added to the Fosamax MDL.

The Food and Drug Administration mandated all bisphosphonate drug manufacturers to update warning labels to include long term side effects such as bone injuries and femur fracture injuries.

It is recommended that anyone who has taken Fosamax, Boniva, or Reclast seek medical help if they experience symptoms of possible bone injuries which may include groin or thigh pain.

Bisphosphonate drugs are bone strengthening medications and are prescribed to women who suffer osteoporosis, a chronic condition which often leads to bone breakage. Fosamax is the most widely taken bisphosphonate in the U.S. and generated $3 billion in sales for Merck prior to the release of a generic version.

Victims continue to sue Merck for Fosamax® femur fractures

Consumer Drug Report recently reported a case filed by another victim of Fosamax femur fracture injuries. According to the drug risk information resource, a woman by the name of Reba Inez Patton and her husband Patrick Patton filed a claim alleging that bisphosphonate medication, Fosamax and Boniva®, caused her to suffer from a low-energy femur fracture in December 2010. The fracture is a rare form of bone injury which may occur with little or no trauma to the victim.

The Fosamax lawsuit was filed on December 15, 2011 against drug maker Merck & Co., maker of Fosamax, and GlaxoSmithKline (GSK), maker of Boniva, in the Superior Court of New Jersey.

The complaint filed by the Patton’s alleges that both Merck and GSK falsely marketed the medications, which are designed to strengthen bones in women diagnosed with osteoporosis, claiming that the companies failed to provide sufficient warnings of the femur fracture risks.

Due to the femur fracture injuries, Mrs. Patton suffers severe and permanent damage requiring ongoing medical care.

Thousands of Fosamax femur fracture lawsuits have been filed against Merck & Co. all of which make similar allegations that the drug company failed to properly warn of the risks associated with long term use of Fosamax.

Fosamax was designed to treat osteoporosis, a chronic condition in which bones become brittle and break. The Food and Drug Administration approved Fosamax in October of 1995. Since its approval, over 20 million patients have taken the medication. The drug grew in popularity and prior to the release of a generic, Fosamax brought in revenues of $3 million.

All lawsuits filed against Merck have been consolidated as part of a multidistrict litigation and is centralized in the U.S. District court for the District of New Jersey.

Fosamax® linked to multiple side effects

Fosamax is now being linked to multiple side effects according to the resource for drug information site Consumer Drug Report. According to the report, Fosamax, a bisphosphonate drug designed to treat osteoporosis, is being linked to a number of adverse side effects.

Victims who have taken the medication say that injuries associated with Fosamax use include osteonecrosis (ONJ), also known as “dead jaw”, atypical femur fracture injuries, atrial fibrillation, and esophageal cancer.  

Merck & Co., manufacturer of Fosamax, claims that these side effects were questionable during their own clinical trials. The company also released a statement, countering arguments that the drug causes ONJ, which said “In worldwide post-marketing experience with Fosamax, Fosamax Plus D, rare reports consistent with osteonecrosis of the jaw have been received. Many of these reports lack sufficient clinical details to make definitive assessments or are confounded, particularly since a generally accepted definition of ONJ in the general population is unknown."

Fosamax attorneys have filed Fosamax lawsuits on behalf of victims affected by the injuries allegedly caused by Fosamax. Merck now faces thousands of lawsuits all involving similar allegations that the manufacturer failed to properly warn about the risks associated with the medication. The company is also accused of falsely marketing Fosamax for the treatment of osteoporosis.

These lawsuits have been consolidated into a multidistrict litigation and centralized in the U.S. District Court for the District of New Jersey.

In October 2010, the Food and Drug Administration mandated that Merck update the product with new warning labels displaying the risk of femur fractures associated with Fosamax use.

Fosamax was approved by the Food and Drug Administration in October of 1995. It was approved to treat osteoporosis in postmenopausal women. Over 20 million patients have been prescribed Fosamax since its approval and it generated $3 million per year in sales prior to the release of a generic version.

Merck to battle three Fosamax® lawsuits in 2012

According to Consumer Drug Report, a resource for drug risk information, Merck is scheduled to have three initial Fosamax lawsuits, also known as bellwether trials, this year. The pharmaceutical giant and manufacturer of Fosamax is being sued by hundreds of individuals for adverse effects allegedly caused by the Fosamax drug.

Fosamax was designed to treat osteoporosis, a chronic condition which may cause bones to become fragile and break. However, according to numerous reports, the drug has been linked to adverse side effects.

The Food and Drug Administration (FDA) approved of Fosamax in October of 1995. Since then, approximately 20 million people have taken the medication. Prior to the release of a generic version of Fosamax, Fosamax brought in annual revenues of $3 million.

Each claim brought against Merck involves similar allegations that Fosamax causes osteonecrosis (ONJ) or “dead jaw,” a condition in which the jaw bone starts to deteriorate and may cause the jaw to show through the skin. As a result of this condition, full or partial jaw removal is often required. Other allegations against the company include claims that Fosamax causes atypical femur fractures. These femur fracture injuries are said to occur during normal activities such as walking or jogging.

Merck currently faces approximately 1,000 product liability lawsuits. Some claims state that the drug causes ONJ while others claim that the drug caused them to suffer atypical femur fractures. All federal cases filed by plaintiffs who claim Fosamax causes ONJ are consolidated before Judge Keenan in the U.S. District Court for the Southern District of New York as part of multidistrict litigation (MDL). All cases filed by plaintiffs who claim Fosamax causes atypical femur fractures have been consolidated as part of a different MDL and is centralized in the U.S. District Court for the District of New Jersey.